吴捷 |
1.心血管药理学
2.离子通道调控及遗传性心律失常分子机制研究
1.遗传性隐匿性1型长QT综合征分子机制研究(No.81470378;资助经费:73万元,2015.1-2018.12)
2.利用转基因表达心脏 Kv1.5钾离子通道研究新型房颤治疗药物(No.81273501;资助经费:70万元,2013.1-2016.12)
1. Wu J(通讯作者), Ding WG, Horie M. Molecular pathogenesis of long QT syndrome type 1 (review). J Arrhythm. 2016; 32:381.
2. 翟晓晨, 吴捷(通讯作者). 三七总皂苷对脑缺血/再灌注损伤保护机制的研究进展. 中国药学杂志. 2016; 151: 24-27.
3. 董超,高洁,翟晓晨,吴捷(通讯作者). Kv1.5钾离子通道阻滞剂的研究进展. 中国药理学与毒理学杂志. 2016; 30:1097-1101.
4. Wu J, Naiki N, Ding WG, Ohno S, Kato K, Zang WJ, Matsuura H, Horie M. A Molecular Mechanism for Adrenergic- induced Long QT Syndrome. J Am Coll Cardiol. 2014; 63(8): 819. (IF:16.503)
5. Zhou J, Ding WG,Makiyama T, Miyamoto A, Matsumoto Y, Kimura H, Tarutani Y, Zhao J, Wu J (通讯作者), Zang WJ, Matsuura H, Horie M. A novel HCN4 mutation, G1097W, is associated with atrioventricular block. Circ J. 2014; 78(4): 938. (IF:3.96)
6. Wu J, Ding WG,Zhao J,Zang WJ, Matsuura H,Horie M. Irbesartan mediated AT1 receptor blockade attenuates hyposmostic-induced enhancement of IKs current and prevents shortening of action potential duration in atrial myocytes. J Renin Angiotensin Aldosterone Syst. 2014;15: 341-347. (IF:2.4).
7. Wu J, Ding WG, Matsuura H, Horie M. Regulatory mechanisms underlying the modulation of GIRK1/GIRK4 heteromeric channels by P2Y receptors. Pflugers Arch. 2012; 464:625. (IF:4.87)
8. Nakajima T, Wu J (并列第一作者), Kaneko Y, Ashihara T, Ohno S, Irie T, Ding WG, Matsuura H, Kurabayashi M, Horie M. KCNE3 T4A as the genetic basis of brugada-pattern electrocardiogram. Circ J. 2012; 76: 2763. (IF:3.58)
9. Wu J, W Shimizu, W-G Ding, Ohno S, Toyoda F, Itoh H, W-J Zang, Miyamoto Y, Kamakura S, Matsuura H, Nademanee K, Brugada J, Brugada P, Brugada R, Vatta M, Towbin JA, Antzelevitch C, Horie M. KCNE2 Modulation of KV4.3 Current and its Potential Role in Fatal Rhythm Disorders. Heart Rhythm 2010; 7:199. (IF:5.05)
10. Wu J, Ding W-G, Matsuura H, Tsuji K, Zang W-J, Horie M. Inhibitory actions of the phosphatidylinositol 3-kinase inhibitor LY294002 on the human Kv1.5 channel. Br J Pharmacol. 2009; 156:377. (IF:5.20)
11.Itoh H, Crotti L, Aiba T, Spazzolini C,Denjoy I, Fressart V, Hayashi K, Nakajima T, Ohno S, Makiyama T, Wu J, Hasegawa K,Mastantuono E, Dagradi F, Pedrazzini M, Yamagishi M, Berthet M,Murakami Y, Shimizu W, Guicheney P, Schwartz PJ, Horie M. The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur Heart J. 2016; 37:1456-1464. (IF:19.651)
12. Kato K, Makiyama Y, Wu J, Ding WG, Kimura H, Naiki N, et al. Cardiac Channelopathies Associated with Infantile Fatal Ventricular Arrhythmias: From the Cradle to the Bench. J Cardiovasc Electrophysiol. 2014; 25: 66. (IF:3.48)
13.Wang Q, Ohno S, Ding WG, Fukuyama M, Miyamoto A, Itoh H, Makiyama T, Wu J, et al. Phenotype variability in patients carrying KCNJ2 mutations. Cardiovasc Electrophysiol. 2014; 25:522. (IF:3.48)
14.Kimura H, Zhou J, Kawamura M, Itoh H, Mizusawa Y, Ding WG, Wu J,et al. Phenotype variability in patients carrying KCNJ2 mutations.Circ Cardiovasc Genet. 2012; 5: 344. (IF:6.73)
15.Li P, Ninomiya H, Kurata Y, Kato M, Miake J, Yamamoto Y, Igawa O,Nakai A, Higaki K, Toyoda F, Wu J, et al. Reciprocal control of hERG stability by Hsp70 and Hsc70 with implication for restoration of LQT2 mutant stability. Circ Res. 2011; 108: 458. (IF:11.86)
16.Gong YZ, Ding WG, Wu J, Tsuji K, Horie M, Matsuura H. Cinnamyl-3,4-dihydroxy-α-cyanocinnamate and nordihydroguaiaretic acid inhibit human Kv1.5 currents independently of lipoxygenase. Eur J Pharmacol. 2008; 600:18. (IF:2.79)
17.Lu J, Zhu SM, Zang WJ, Xu XL, Wu J, Horie M, et al. Protective mechanism of adenosine to the rat arterial endothelial dysfunction induced by hydrogen peroxide. Biol Pharm Bull. 2007; 30:1206. (IF:2.00)
18.Nagaoka I, Matsui K, Ueyama T, Kanemoto M, Wu J, Horie M, et al.A novel mutation of plakophilin-2 associated with arrhythmogenic right ventricular cardiomyopathy. Circ J. 2006; 70:933. (IF:3.58)